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ORIGINAL ARTICLE
More Dose-dependent Side Effects with Mercaptopurine over
Azathioprine in IBD Treatment Due to Relatively Higher Dosing
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Geert J. A. Wanten, MD, PhD,* Dennis R. Wong, PharmD, PhD,‡ Andre L. M. Verbeek, MD, PhD,§
Olaf H. Klungel, PharmD, PhD,k Piet M. Hooymans, PharmD, PhD,‡ Henk-Jan Guchelaar, PharmD, PhD,¶
Hans Scheffer, PhD,† Luc J. J. Derijks, PharmD, PhD,** and Dirk J. de Jong, MD, PhD,* TOPIC Recruitment
Team
Background: There are substantial global differences in the preference for mercaptopurine (MP) or its prodrug azathioprine (AZA) as ﬁrst-choice
thiopurine to treat inﬂammatory bowel diseases. Studies comparing both agents are scarce. Our aim was to compare AZA and MP in thiopurine-naive
patients with inﬂammatory bowel disease for the frequency of side effects and efﬁcacy.
Methods: Post hoc analysis of the “Thiopurine response Optimization by Pharmacogenetic testing in Inﬂammatory bowel disease Clinics” (TOPIC)
trial, in which thiopurine-naive patients with inﬂammatory bowel disease with an indication for a thiopurine were randomized for a genotype-based dose
versus standard of care. For this study, Cox proportional hazard ratios (HRs) were calculated to compare AZA and MP for discontinuation rates within 5
months, incidence of hepatotoxicity, leukopenia, and gastrointestinal side effects. Treatment efﬁcacy was compared by logistic regression.
Results: Patient characteristics were similar for patients treated with AZA (n ¼ 494, 64.4%) and MP (n ¼ 273, 35.6%), yet patients with MP were
relatively higher dosed compared with those on AZA. Discontinuation rates within 5 months were not different, 39.3% (AZA) and 38.1% (MP), HR 0.92
(95% conﬁdence interval, 0.72–1.17; P ¼ 0.50); however, patients on MP were more often subjected to dose reductions (30% versus 14%, P , 0.01).
Higher rates of hepatotoxicity, HR 1.93 (95% conﬁdence interval, 1.35–2.76; P , 0.01) and leukopenia, HR 2.55 (95% conﬁdence interval, 1.51–4.30;
P , 0.01) were observed with MP, which annulled in a secondary analysis with adjustment for the higher dose and metabolite levels.
Conclusions: Patients treated with MP were relatively higher dosed, which resulted in more dose-dependent side effects and a higher rate of dose reductions.
(Inﬂamm Bowel Dis 2017;0:1–9)
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T hiopurines have a central role in the treatment of inﬂammatorybowel diseases (IBDs) and are also used in the treatment
of numerous immune-mediated diseases and malignancies as
well as for the prevention of posttransplantation organ rejection.1–3
Azathioprine (AZA) and mercaptopurine (MP) are classiﬁed
as the conventional thiopurines. Both agents have proven
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efﬁcacy in the treatment of Crohn’s disease (CD) and
ulcerative colitis (UC).4–7 Unfortunately, the use of
thiopurines is frequently accompanied by side effects such as
hepatotoxicity, gastrointestinal complaints, and ﬂu-like symptoms
or leukopenia, often leading to premature treatment
discontinuation.8,9
After absorption, AZA is metabolized to MP, and further
metabolism leads to the formation of several metabolites of which
6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine
ribonucleotides (6-MMPR) are considered to be the most
important.10 Current guidelines for IBD express no preference
for AZA or MP because an equal efﬁcacy is assumed and head-
to-head comparisons are lacking.5,11,12 Accompanied with
marketing-related issues, this has led to major global differences
in the preference for AZA or MP as ﬁrst-choice thiopurine to treat
IBD.13 Although many studies have reported on thiopurine-
induced side effects, none of these focused on a direct comparison
of AZA and MP, or these investigations were limited by the fact
that one drug was overrepresented in the study population.14–17
Nevertheless, some reports showed differences between
AZA and MP in terms of side effects.18 The methylnitroimidazole
group, which is released in the conversion of AZA to MP, has
been associated with gastrointestinal side effects, but also with
enhanced immunosuppressive effects.19,20 Furthermore, genetic
variants in glutathione transferase, an enzyme involved in the
conversion of AZA to MP, might affect thiopurine metabolite
levels in patients on AZA but not in those on MP.21,22 Recent
data suggest that MP might be considered as an alternative in
patients intolerant to AZA.23,24 Notably, if AZA and MP would
have been developed in the current era, randomized blinded trials
would have been mandatory to compare their safety and efﬁcacy
proﬁles before routine use. Such data are currently lacking and
given the cost of such studies and relatively low ﬁnancial impli-
cations, it is highly unlikely that such trials will ever be per-
formed. In the present post hoc analysis of the “Thiopurine
response Optimization by Pharmacogenetic testing in Inﬂamma-
tory bowel disease Clinics” (TOPIC) trial, we evaluated the
hypothesis that AZA and MP are equally effective and safe in
the treatment of thiopurine-naive patients with IBD.
PATIENTS AND METHODS
Patients
The study design, patient data, and results of the TOPIC
trial have been published previously.25 Brieﬂy, thiopurine-naive
patients with IBD with an indication for thiopurine treatment were
randomized 1:1 for thiopurine dosing based on their thiopurine S-
methyltransferase (TPMT) genotype versus the standard AZA
(2.0–2.5 mg/kg) or MP dose (1.0–1.5 mg/kg). Patients assigned
to the TPMT genotyping arm received a 50% dose reduction when
they carried a heterozygote variant in TPMT*2, TPMT*3A, or
TPMT*3C, whereas carriers of a homozygote variant received
10% of the original dose or were advised to start an alternative
treatment. Patients assigned to the standard-of-care arm were gen-
otyped for variants in TPMT afterward. TPMT activity was
assessed in all patients after the execution of the clinical trial.
Indication for thiopurine treatment was determined by the
treating physician. Indication was not reported on the case report
form. Physicians were free in the choice whether to start AZA or
MP, and advised to start full regular dose immediately. The main
exclusion criteria of the TOPIC trial were previous use of
thiopurines, cotreatment with allopurinol, a baseline white blood
cell count ,3.0 · 109/L, and baseline liver test abnormalities
(alanine transaminase [ALT], aspartate transaminase [AST], or
alkaline phosphatase) $2 times the normal upper limit (ULN),
a known TPMT enzyme activity or TPMT genotype. Biochemical
and hematological safety parameters were assessed at baseline and
weeks 1, 2, 4, 6, 8, and 20. The patients were followed for 20
weeks. The TOPIC trial was approved by the institutional ethic
committees, and all patients provided written informed consent
(clinicaltrials.gov, NCT00521950).
6-MMPR and 6-TGN Metabolite Levels
Week 8 6-MMPR and 6-TGN metabolite levels were
assessed in red blood cells by high-performance liquid chroma-
tography, according to the Lennard method and reported as
median pmol/8 · 108 red blood cells with the interquartile range
(IQR).25 Week 8 levels were assessed in the ﬁrst 301 patients
included in the TOPIC trial. Next to week 8 levels, 6-MMPR,
and 6-TGN levels were also assessed at week 1 in 267 patients
according to the same method.26,27
Study Design
In this study, we compared AZA and MP for their safety
and efﬁcacy. All patients who complied with the study protocol
and started with AZA or MP were included in an intention-to-treat
analysis. The AZA dosage in mg/kg bodyweight was divided by
2.08 for comparison with the MP dose. The molecular weight
of MP (Mw ¼ 152.18 g/mol) is 55% of the molecular weight of
AZA (Mw ¼ 277.27 g/mol), resulting in a conversion factor of
2.08 (1/0.55–1/0.88), when converting MP into an equivalent
pharmaceutical dose of AZA, assuming 100% bioavailability.18,28
In 30 patients, the dose was escalated within 1 or 2 weeks. In
these cases, we used the ﬁnal dose for analysis.
The primary outcome was the proportion of the patients
who were still using the initial thiopurine after 5 months. Dose
reductions and temporarily interruption were accepted; however,
when the thiopurine was discontinued for more than 20% of the
study time (1 month or longer), the primary endpoint was not
reached. If the indication for discontinuation after temporarily
interruption was identical to the ﬁnal reason to stop, the ﬁrst date
of discontinuation was used for analysis. When a different
indication led to deﬁnite treatment discontinuation after tempo-
rarily discontinuation, the last date was used for analysis.
Secondary outcomes were signs of hepatotoxicity (deﬁned
as increase more than 2 times the ULN of ALT or conjugated
bilirubin, or a combined increase in AST and alkaline phosphatase
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provided that one of them is above 2 times the ULN).29 When
baseline levels were between 1 and 2 times the ULN, a 2-time
increase of the baseline value was required. Furthermore, the
frequency of gastrointestinal side effects (deﬁned as occurrence
of nausea, vomiting, or decreased appetite during the study as
reported by the patient), leukopenia (deﬁned as a white blood cell
count #3.0 · 109/L), and the incidence of thiopurine-induced
pancreatitis (TIAP) were compared for AZA and MP. TIAP
was deﬁned as the presence of amylase or lipase 3 times the
ULN according to the reference value of the local laboratory in
combination with radiological or clinical signs suggestive for
pancreatitis in the absence of another likely cause.30 Treatment
response was evaluated using the Harvey–Bradshaw index in CD
and partial Mayo score in UC. Treatment response was deﬁned as
a reduction of 3 points or more at week 20 compared with week 0.
Statistical Analysis
All the statistical analyses were performed using SPSS
version 20.0.0.1 (SPSS Inc., Chicago, IL). The patient character-
istics between patients on AZA and MP were compared by the
chi-square test for dichotomous variables, and student’s t tests or
Mann–Whitney U tests were used for continuous variables. We
performed Cox proportional hazards survival analysis to calculate
the hazard ratio for AZA and MP with 95% conﬁdence intervals
(CIs) for the time to treatment discontinuation, gastrointestinal
side effects, signs of hepatotoxicity, and leukopenia.
Kaplan–Meier curves with separate lines for AZA and MP were
plotted to illustrate differences in treatment discontinuation, gas-
trointestinal side effects, signs of hepatotoxicity, and leukopenia.
Log-rank tests were used to compare the Kaplan–Meier curves.
Secondary multivariate Cox proportional hazard models
were computed to calculate the hazard ratio for AZA and MP
adjusted for confounders. Differences in the patient characteristics
between AZA and MP users with a P-value ,0.1 were included
in a Cox proportional hazard model to calculate the adjusted
hazard ratio with 95% CIs for AZA compared with MP for the
primary outcome treatment discontinuation as well as the second-
ary outcome signs of hepatotoxicity, leukopenia, and gastrointes-
tinal side effects. As follows from the comparison of baseline
characteristics between AZA and MP, metabolite levels were
included as covariate in this analysis. Week 1 metabolite data
were chosen instead of week 8 levels because most adverse
events, among others, hepatotoxicity and leukopenia, occurred
in the ﬁrst weeks of treatment initiation. As a consequence, week
8 metabolite levels were either biased in these patients because of
already applied dose reductions or were not available because of
treatment discontinuation before week 8 because of the adverse
event. Moreover, patients with severe hepatotoxicity or leukope-
nia are more likely to be subjected to dose reductions or treatment
discontinuation, which also might lead to biased results. With the
use of week 1 metabolite levels, this was obviated because
patients did not develop the adverse event yet. Week 1 metabolite
levels were available for 267 patients, and Cox proportional
hazard analyses were performed in these patients.
The treatment response in AZA and MP was compared by
the chi-squared test. For further analysis, the response rates in CD
and UC were merged to have sufﬁcient numbers. Logistic
regression was used to calculate the odds ratio of treatment




In the TOPIC trial, 796 patients were randomized, of whom
29 did not start with a thiopurine or were excluded because of
protocol violations.25 The remaining 767 patients treated with
either AZA (n ¼ 494, 64.4%) or MP (n ¼ 273, 35.6%) were
included in this analysis. The baseline characteristics of both
groups are depicted in Table 1 and showed no differences
between AZA and MP users except for the median dose in mg/
kg, which was higher in patients taking MP (1.21 mg/kg, IQR
1.10–1.30) compared with the converted rate of AZA (1.05 mg/
kg, IQR 0.99–1.11), P , 0.001. Furthermore, both week 1 and
week 8 6-MMPR and 6-TGN metabolite levels were signiﬁcantly
higher in patients treated with MP (Table 1). Otherwise, no differ-
ences in characteristics were observed between the patients as-
signed to AZA and MP.
Treatment Discontinuation
Overall, 298 patients (38.9%) discontinued the initial
thiopurine within 5 months after starting treatment. In patients
taking AZA, n ¼ 194 (39.3%) discontinued treatment and in
patients taking MP, n ¼ 104 (38.1%), P ¼ 0.75. The
Kaplan–Meier curves showed no difference in treatment discon-
tinuation rates between AZA and MP, P ¼ 0.57 (Fig. 1). The
hazard ratio for AZA versus MP with 95% CIs for discontinuation
in the ﬁrst 5 months was 0.92 (0.72–1.17; P ¼ 0.50).
Of the patients still taking the initial prescribed thiopurine
at week 20 (n ¼ 469), those treated with MP were more often
subjected to dose reductions compared with the patients treated
with AZA (30.1% versus 13.7%, P , 0.001). In addition, at week
20, the median dose of the patients still taking the initial
prescribed thiopurine was signiﬁcantly more decreased in patients
taking MP (n ¼ 168), 1.14 mg/kg (IQR 0.82–1.25), compared
with those treated with AZA (n ¼ 300), 1.04 mg/kg (IQR
0.96–1.11), P , 0.001.
Signs of Hepatotoxicity
Signs of hepatotoxicity (deﬁned as more than 2 times the
ULN increase of ALT or conjugated bilirubin, or a combined
increase in AST and alkaline phosphatase provided that one of
them is above 2 times the ULN) were reported in 59 patients
treated with AZA (11.9%) and in 62 patients taking MP (22.7%),
hazard ratio 1.93 (95% CI, 1.35–2.76; P , 0.001). In 88% of the
patients (106 of 121) with hepatotoxicity, this developed in the ﬁrst
8 weeks of treatment. Time to hepatotoxicity was not signiﬁcantly
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different between AZA and MP (P ¼ 0.64) (Fig. 2). The median
(IQR) rise of ALT was not different between AZA users, 90 U/L
(65–148), and MP users, 96 U/L (68–133), P ¼ 0.83 (Fig. 3).
Because patients with MP were relatively higher dosed
and, therefore, probably showed higher metabolite levels, we
also calculated the hazard ratio adjusted for these variables.
This secondary analysis in 267 patients, with adjustment for
dosage in mg/kg and week 1 6-MMPR and 6-TGN metabolite
levels, showed a hazard ratio of 1.79 (95% CI, 0.82–3.92; P ¼
0.15).
Leukopenia
Leukopenia (deﬁned as a white blood cell count #3.0 ·
109/L) was observed in 58 patients (7.6%). Eight of these pa-
tients (4 patients on AZA and 4 on MP) had a variant in TPMT
and were randomized to the standard-of-care group and sub-
sequently received the standard thiopurine dose. Leukopenia
was observed in 24 patients (4.9%) treated with AZA and in
34 patients (12.5%) treated with MP, hazard ratio 2.55 (95%
CI, 1.51–4.30; P , 0.001). Secondary analysis with adjustment
for dosage in mg/kg and week 1 6-MMPR and 6-TGN
TABLE 1. Baseline Characteristics of the Patients on AZA (AZA Users) and MP (MP Users)
Total AZA Users MP Users P
Total, n (%) 767 (100) 494 (64) 273 (36)
Sex, male, n (%) 346 (45) 220 (46) 126 (47) 0.66
Age, yr, median (IQR) 40.5 (26.6–53.0) 40.1 (26.5–52.7) 41.3 (26.6–54.3) 0.43
Weight, kg, mean (SD) 74.4 (16.1) 74.2 (14.9) 74.6 (18.2) 0.72
Disease, n (%)
CD 463 (60) 297 (60) 166 (61)
UC 297 (39) 194 (39) 103 (38)
Indeterminate colitis 7 (1) 3 (1) 4 (2) 0.74
Study arm, n (%)
Genotyping 398 (52) 253 (51) 145 (53)
Standard 369 (48) 241 (49) 128 (47) 0.61
Heterozygous TPMT genotype, n (%) 72 (9) 46 (9) 26 (10) 0.92
TPMT activity, mg/mmol Hb.h, mean (SD) 90.3 (22.4) 90.5 (22.9) 90.0 (21.5) 0.78
Dosage, mg/kg, median (IQR)a 2.18 (2.07–2.31) 1.21 (1.10–1.30) —
Dosage after conversion by 2.08, median (IQR)b 1.05 (0.99–1.11) 1.21 (1.10–1.30) ,0.001
Baseline disease activity
CD (HBI), mean (SD)c 3.5 (3.0) 3.4 (2.9) 3.6 (3.3) 0.57
UC (partial Mayo), mean (SD)d 3.8 (1.7) 3.8 (1.7) 3.9 (1.8) 0.58
Comedication during the trial, n (%)
5-aminosalicylic acid 385 (50) 253 (51.2) 132 (48.4) 0.45
Corticosteroidse 440 (58) 275 (55.9) 165 (60.4) 0.18
Biologics 82 (11) 49 (10) 33 (12) 0.35
Metabolite levels, pmol/8 · 108 RBCs
Week 1 6-TGN levels, median (IQR) 152 (110–206) 134 (100–186)f 189 (129–241)g ,0.001
Week 1 6-MMPR levels, median (IQR) 2013 (946–3595) 1802 (897–3119)f 3051 (1069–5716)g ,0.001
Week 8 6-TGN levels, median (IQR) 243 (179–366) 221 (169–337)h 269 (196–391)i 0.04
Week 8 6-MMPR levels, median (IQR) 2908 (771–6592) 2274 (678–5270)h 4147 (1027–10,651)i 0.003
aDose levels include 38 patients (AZA n ¼ 24 and MP n ¼ 14, P ¼ 0.98) with a heterozygous TPMT variant randomized to the genotype arm and subsequently received a 50% dose
reduction from the start according to the study protocol.
bAZA dose as divided by 2.08.
cAvailable for 349 patients.
dAvailable for 251 patients.
eAvailable for 763 patients, steroids with limited systemic bioavailability, such as budesonide, were not included.
fAvailable for 182 patients.
gAvailable for 85 patients.
hAvailable for 150 patients.
iAvailable for 84 patients.
HBI, Harvey–Bradshaw index; RBCs, red blood cells.
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metabolite levels showed a hazard ratio of 0.92 (95% CI,
0.28–3.05; P ¼ 0.89). The time to development of leukopenia
was not signiﬁcantly different between AZA and MP (P ¼
0.62) (Fig. 4).
Gastrointestinal Side Effects
Gastrointestinal side effects were reported by 345
patients (45.0%), of whom 216 patients (43.7%) were treated
with AZA and 129 patients (47.3%) with MP, hazard ratio
1.09 (95% CI, 0.87–1.3; P ¼ 0.46). Median time to the
occurrence of gastrointestinal side effects was 14 (range,
7–34) days. No difference was observed in the
Kaplan–Meier curve between AZA and MP, P ¼ 0.52 (Fig.
5). In the secondary analysis, the hazard ratio for AZA or MP
on gastrointestinal side effects was hazard ratio 1.38 (95% CI,
0.90–2.10; P ¼ 0.17).
Thiopurine-induced Acute Pancreatitis
In total 14 patients (1.8%), of whom 11 on AZA (2.2%) and
3 on MP (1.1%) developed a TIAP for which the initial thiopurine
was stopped. Characteristics of patients with a TIAP are depicted
in Table 1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B529. Mean time to TIAP was 20 6 5 days, and no cases of
severe (necrotizing) pancreatitis were reported. One patient with
a TIAP on AZA was later switched to MP; however, this was
stopped after 1 day because of fever (no laboratory measurements
were performed).
Treatment Efﬁcacy
Information about treatment response was available for 351
patients (45.7%), AZA (n ¼ 242) and MP (n ¼ 109). Baseline
disease activity scores (mean 6 SD) were not different for
patients of whom treatment response was known or unknown
(Harvey–Bradshaw index, 3.43 6 2.88 versus 3.62 6 3.36,
P ¼ 0.63) and (partial Mayo score, 3.74 6 1.73 versus 3.90 6
1.70, P ¼ 0.50), respectively. In CD, 38 patients on AZA (26%)
and 21 patients on MP (26%) achieved a reduction in the
FIGURE 1. Time to treatment discontinuation for patients assigned to
AZA and MP. No difference in treatment discontinuation was observed
between AZA and MP, P ¼ 0.57.
FIGURE 2. Time to development of signs of hepatotoxicity (deﬁned as
more than 2 times the ULN increase of ALT or conjugated bilirubin, or
a combined increase in AST and alkaline phosphatase provided that
one of them is above 2 times the ULN) in patients taking AZA or MP.
No difference was observed in the time to the development of signs of
hepatotoxicity between AZA and MP (P ¼ 0.64).
FIGURE 3. Maximum increase in ALT in units/litre compared with
baseline in patients on AZA (n ¼ 59) and patients on MP (n ¼ 62) who
developed signs of hepatotoxicity. No difference was observed
between AZA and MP (P ¼ 0.83).
FIGURE 4. Time to development of leukopenia (deﬁned as a white blood
cell count#3.0 · 109/L) in patients taking AZA or MP. No difference was
observed between patients on AZA and MP (P ¼ 0.62).
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Harvey–Bradshaw index of 3 points or more, P ¼ 0.90. In UC,
a reduction in the partial Mayo score of 3 points or more was seen
in 22 patients on AZA (24%) and 9 patients on MP (32%), P ¼
0.42. For further analysis, the response rates in CD and UC were
merged to have sufﬁcient numbers. No difference in treatment
response was observed between AZA (26%) and MP (27%), odds
ratio 1.12 (95% CI 0.67–1.87; P ¼ 0.66). In this group, week 1
metabolite levels and thiopurine dose were available for 126
patients. Secondary analysis in this group with adjustment for
week 1 metabolite levels and thiopurine dose did not inﬂuence the
odds ratio 1.11 (95% CI, 0.44–2.88; P ¼ 0.88).
DISCUSSION
Our data showed that in thiopurine-naive patients with IBD,
the treatment discontinuation rates within the ﬁrst 5 months were
similar between AZA and MP users. The higher rates of signs of
hepatotoxicity and leukopenia in patients taking MP are most
likely explained by the relatively higher average dose and
subsequent higher 6-MMPR and 6-TGN metabolite levels
compared with patients with AZA, rather than by interdrug
differences. Furthermore, no differences were found in treatment
efﬁcacy and gastrointestinal side effects.
The baseline characteristics were similar for the patients on
AZA and MP. This excluded a preference for one of both agents
in particular patient groups. Our data on dosage and metabolite
levels showed that patients with MP were relatively higher dosed
in mg/kg bodyweight compared with AZA users. This might well
explain the higher rates of dose-dependent side effects like
leukopenia and signs of hepatotoxicity with MP.31 Adjustment
for the baseline differences in thiopurine dose and week 1 metab-
olite levels annulled these higher rates of side effects. Week 1
6-MMPR and 6-TGN levels have been shown to be promising
factors to predict leukopenia and hepatotoxicity.26,27 Most side
effects were seen in the ﬁrst weeks of treatment initiation and
often led to dose reduction or treatment discontinuation. As a con-
sequence, steady-state week 8 metabolite levels were not available
or biased because of dose reductions in these patients. For this
reason, we used week 1 metabolite levels for our secondary anal-
ysis. Both drug dose and thiopurine metabolite levels were sig-
niﬁcantly higher in MP users. Because most studies showed no
clear correlation between drug dose and thiopurine metabolite
levels, we included both variables in the multivariate analysis.32,33
Current studies exploring the safety proﬁle of thiopurines
are mostly limited by the inclusion of patients only taking AZA or
MP.15,16,34 This problem is mainly due to global variation in the
preference for either AZA or MP and is partly caused by the fact
that not everywhere both drugs are registered for the treatment of
IBD.13 Although not speciﬁcally designed for this purpose, some
studies did compare AZA and MP in their analysis. In a recent
study, a 5-fold higher rate of leukopenia was found in patients
taking MP compared with AZA.14 Despite the large study pop-
ulation of almost 4000 patients, the lack of detailed information
on the dosage and metabolite levels precluded detailed dose-
related analysis as in our study. The incidence of hepatotoxicity
in the current study was 15.8%, which is within the range of the
highly variable incidence reported in previous studies.9,35 This
wide range (4%–17%) is probably the result of differences in
study protocols and deﬁnitions of drug-induced liver toxicity.35
The frequent routine laboratory controls in the TOPIC trial in
combination with our criteria for hepatotoxicity and the fact that
in the TOPIC trial patients started with the full regular dose prob-
ably contributed to the high rate found in our study. Present
criteria for drug-induced liver toxicity include an increase of
ALT or AST 5 times the ULN.36 Only 11 patients in our study
would meet these criteria, yet most of the patients with liver test
abnormalities between 2 and 5 times the ULN received a dose
reduction or the treatment was (temporarily) discontinued. Given
the clinical relevance, we applied the more liberal criteria formu-
lated by Benichou.29 There are many factors involved in the
development of thiopurine-induced hepatotoxicity, including
thiopurine dose, bodyweight, sex, and age.27
In the TOPIC trial, patients were randomized for dose
adjustment based on their TPMT genotype versus standard dosing.
This resulted in a group of patients with a heterozygous variant in
TPMT treated with the standard dose as well as a group who
received 50% of the standard dose. Table 2, Supplemental Digital
Content 2, http://links.lww.com/IBD/B530 provides detailed
information about side-effect rates for these different groups.
Absolute numbers are low, which precludes additional analyses
to compare AZA with MP within these subgroups. However,
taking the small groups into account, no large differences were
seen between AZA and MP with respect to hepatotoxicity,
leukopenia, and gastrointestinal side effects.
As mentioned above, our results show that when ofﬁcial
clinical guidelines are applied, MP is prescribed in a relatively
higher dose than AZA. This ﬁnding has been described
previously in a large retrospective analysis, where patients
with AZA received 1.94 mg/kg (0.93 mg/kg after conversion by
2.08) and MP was dosed at around 1.20 mg/kg.8 A reason
might be that the only available pharmaceutical dosage form
FIGURE 5. Time to development of gastrointestinal side effects in
patients taking AZA or MP. No difference was observed between AZA
and MP (P ¼ 0.52).
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of MP is 50 mg, whereas for AZA, there are 25 and 50 mg
tablets available in Europe. Introduction of 25 mg tablets of MP
(and AZA, if not yet available) would allow more accurate
dosing and will circumvent the need of scoring tablets to
acquire the optimal tailored dose. In addition, given that the
absolute dosage is lower in MP, increasing the dose with 25 or
50 mg leads to a larger effect in terms of percentages in a patient
on MP compared with a patient taking AZA. Another explana-
tion might be that in clinical practice, a more convenient
conversion rate of 2.0 is used instead of 2.08 to calculate the
AZA dose from the equivalent MP dose.28 Current guidelines
recommend AZA in a dose between 2.0 and 2.5 mg/kg and MP
between 1.0 and 1.5 mg/kg; however, when the 2.08 rate is
applied to the recommended AZA dose, MP should actually
be dosed between 0.96 and 1.20 mg/kg.6,37,38 The equal dis-
continuation rates, despite more dose-dependent side effects
with MP, can be explained by the higher rate of dose reductions
applied in patients treated with MP. This advocates for
a slightly lower starting dose of MP.
In the TOPIC trial, a high rate (38.9%) of treatment
discontinuation was observed within the ﬁrst 5 months, primarily
because of side effects. This rate is in line with previous studies
which reported discontinuation rates of approximately 30% within
the ﬁrst months.8,39 The high discontinuation rate underlines the
potential impact of thiopurine-induced adverse events. As
expected, gastrointestinal side effects were the most frequently
reported adverse event and occurred in approximately 50% of
the patients. Our data corroborate with a recent study in almost
4000 patients with IBD on thiopurine therapy, which also found
similar rates of gastrointestinal side effects in patients treated with
AZA and MP.14 Some studies have shown the gain of switching
from AZA to MP in the presence of adverse events.24 Although
some patients were rechallenged after discontinuing the initial
thiopurine, no detailed information was available to report on
success rates of this switch.
TIAP is considered to be a non–dose-dependent adverse
reaction linked with single nucleotide polymorphisms in
the class II human leukocyte antigen region but also with
blood group B.40,41 This makes a difference between AZA
and MP in frequency unlikely. Our results showed a higher
rate of TIAP in AZA compared with MP; however, given the
low number of cases, we had insufﬁcient power to perform
statistic analysis.
This study provides novel insights into the comparability of
AZA and MP as a result of some exclusive characteristics. First,
this study focused on the comparison of AZA and MP, which was
possible because of the large number of thiopurine-naive patients
assigned to AZA and MP. In addition, the similarity of the
baseline characteristics does not suggest selection bias.
Limitations of this study are that the current analyses were
not prespeciﬁed in the original study protocol. Furthermore,
week 1 metabolite levels used for the secondary analysis were
only available for 267 patients.26 Importantly, there were no
differences in baseline characteristics between the patients with
known week 1 metabolite data compared with the patients with-
out week 1 metabolite data, Table 3, Supplemental Digital
Content 3, http://links.lww.com/IBD/B531. The use of week 1
metabolite levels is still limited to clinical trials. Secondary
analyses with the use of week 8 metabolite levels instead of
week 1 levels showed consistent results, however with less cases
included, Table 4, Supplemental Digital Content 4, http://links.
lww.com/IBD/B532. Furthermore, in the TOPIC trial, the
Harvey-Bradshaw index and partial Mayo score were used to
assess treatment efﬁcacy. Ideally, colonoscopies should have
been implemented for the assessment of mucosal healing; how-
ever, because the TOPIC trial primarily focused on safety
outcomes rather than effectiveness, these were not included.25
Furthermore, thiopurines were started both for active disease and
maintenance of remission, which limits the assessment of the
treatment effect. Also, the use of co-medication, such as cortico-
steroids or biologic drugs, is an important confounder in the
evaluation of treatment effects. Considering these limitations,
the treatment response of 26% and 27% in AZA and MP users,
respectively, is in line with the data from the SONIC trial.42,43 In
the TOPIC trial, physicians were advised to start the full dose
immediately, in which the recommended dose depended on the
TPMT genotype and whether the patient was randomized to the
intervention arm or not. Beginning with the full thiopurine dose
might result in relative higher rates of side effects compared with
a step-up approach (starting with half the dose and increase to
full dose after 1 or 2 weeks if the drug is tolerated). With a step-
up approach, the difference in dose-dependent side effects
between AZA and MP might decrease because ﬁrst signs of side
effects already may result in a postponement of further increase
to the intended dose.
In conclusion, in this study, we showed that when current
clinical guidelines for IBD are followed, the patients treated with
MP are relatively higher dosed, suffer from higher rates of dose-
dependent side effects, and subsequently need more frequent dose
reductions compared with those treated with AZA. This might be
prevented when the initial MP dose is adjusted to 0.96 to 1.20 mg/
kg bodyweight and 25 mg tablets MP are introduced for a more
accurate tailored dose; however, feature studies are necessary to
further evaluate this. Despite these differences, overall treatment
discontinuation rates were equal for AZA and MP.
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